Viridian therapeutics, inc. (VRDN) 2025Q4 financial report shows revenue of 132K USD, with a YoY growth rate of 83.33%. This outstanding figure clearly proves the company’s exceptionally strong operational momentum and significant expansion in market demand. To accurately capture Viridian therapeutics, inc. (VRDN)’s future growth potential, investors should closely follow subsequent financial reports and key strategic movements, and deeply integrate diversified data and tools such as Growin AI Value Analysis for a comprehensive and forward-looking strategic assessment.